Pedro Gil

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: MALARIA JOURNAL. 2022;21(1):106

Temporal distribution of Plasmodium falciparum recrudescence following artemisinin-based combination therapy: an individual participant data meta-analysis.

WorldWide Antimalarial Resistance Network Methodol
Article: FRONTIERS IN PHARMACOLOGY. 2022;13:868723

Plasmodium falciparum Drug Resistance Genes pfmdr1 and pfcrt In Vivo Co-Expression During Artemether-Lumefantrine Therapy.

Silva M; Malmberg M; Otienoburu SD; Björkman A; Ngasala B; Mårtensson A; Gil JP; Veiga MI
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2021;65(7):e0027521-e00221

Pharmacogene Sequencing of a Gabonese Population with Severe Plasmodium falciparum Malaria Reveals Multiple Novel Variants with Putative Relevance for Antimalarial Treatment.

Pernaute-Lau L; Adegnika AA; Zhou Y; Zinsou JF; Gil JP; Krishna S; Kremsner PG; Lauschke VM; Velavan TP
Article: INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE. 2021;15:9-24

Monitoring Plasmodium vivax resistance to antimalarials: Persisting challenges and future directions.

Ferreira MU; Nobrega de Sousa T; Rangel GW; Johansen IC; Corder RM; Ladeia-Andrade S; Gil JP
Article: MALARIA JOURNAL. 2021;20(1):90

Influence of cytochrome P450 (CYP) 2C8 polymorphisms on the efficacy and tolerability of artesunate-amodiaquine treatment of uncomplicated Plasmodium falciparum malaria in Zanzibar.

Pernaute-Lau L; Morris U; Msellem M; Mårtensson A; Björkman A; Gil JP
Article: MBIO. 2020;11(6):e02093-e02020

Expansion of a Specific Plasmodium falciparum PfMDR1 Haplotype in Southeast Asia with Increased Substrate Transport.

Calçada C; Silva M; Baptista V; Thathy V; Silva-Pedrosa R; Granja D; Ferreira PE; Gil JP; Fidock DA; Veiga MI
Article: CLINICAL THERAPEUTICS. 2020;42(8):1595-1610.e5

Challenges and Opportunities for Clinical Pharmacogenetic Research Studies in Resource-limited Settings: Conclusions From the Council for International Organizations of Medical Sciences-Ibero-American Network of Pharmacogenetics and Pharmacogenomics Meeting.

Peñas-LLedó E; Terán E; Sosa-Macías M; Galaviz-Hernández C; Gil J-P; Nair S; Diwakar S; Hernández I; Lara-Riegos J; Ramírez-Roa R; Verde I; Tarazona-Santos E; Molina-Guarneros J; Moya G; Rägo L; LLerena A
Article: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2020;95:399-405

Different Plasmodium falciparum clearance times in two Malian villages following artesunate monotherapy.

Kone A; Sissoko S; Fofana B; Sangare CO; Dembele D; Haidara AS; Diallo N; Coulibaly A; Traore A; Toure S; Haidara K; Sanogo K; Sagara I; Beshir KB; Gil JP; Doumbo OK; Djimde AA
Article: PHARMACOGENOMICS & PERSONALIZED MEDICINE. 2020;13:571-575

Prevalence of CYP2C8*2 and *3 among Eritreans and its Potential Impact on Artesunate/Amodiaquine Treatment.

Habtemikael L; Russom M; Bahta I; Mihreteab S; Berhane A; Mårtensson A; Gil JP
Article: MALARIA JOURNAL. 2019;18(1):225

Competing risk events in antimalarial drug trials in uncomplicated Plasmodium falciparum malaria: a WorldWide Antimalarial Resistance Network individual participant data meta-analysis.

WorldWide Antimalarial Resistance Network Methodol
Article: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2019;74(7):1890-1893

Plasmodium falciparum K13 expression associated with parasite clearance during artemisinin-based combination therapy.

Silva M; Ferreira PE; Otienoburu SD; Calçada C; Ngasala B; Björkman A; Mårtensson A; Gil JP; Veiga MI
Article: AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE. 2019;100(5):1179-1186

Prevalence of and Risk Factors Associated with Polymerase Chain Reaction-Determined Plasmodium falciparum Positivity on Day 3 after Initiation of Artemether-Lumefantrine Treatment for Uncomplicated Malaria in Bagamoyo District, Tanzania.

Mwaiswelo R; Ngasala B; Jovel I; Xu W; Larsson E; Malmberg M; Gil JP; Premji Z; Mmbando BP; Mårtensson A
Article: LANCET. 2018;391(10128):1378-1390

Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.

West African Network for Clinical Trials of Antima
Article: MALARIA JOURNAL. 2017;16(1):383

The drug transporter ABCB1 c.3435C>T SNP influences artemether-lumefantrine treatment outcome.

Kiaco K; Rodrigues AS; do Rosário V; Gil JP; Lopes D
Article: AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE. 2017;97(2):526-532

Sustained High Cure Rate of Artemether-Lumefantrine against Uncomplicated Plasmodium falciparum Malaria after 8 Years of Its Wide-Scale Use in Bagamoyo District, Tanzania.

Mwaiswelo R; Ngasala B; Gil JP; Malmberg M; Jovel I; Xu W; Premji Z; Mmbando BP; Björkman A; Mårtensson A
Article: PHARMACOGENOMICS. 2017;18(10):981-985

MRP2/ABCC2 C1515Y polymorphism modulates exposure to lumefantrine during artemether-lumefantrine antimalarial therapy.

Vos K; Sciuto CL; Piedade R; Ashton M; Björkman A; Ngasala B; Mårtensson A; Gil JP
Article: LANCET INFECTIOUS DISEASES. 2016;16(2):189-198

Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial.

Sagara I; Beavogui AH; Zongo I; Soulama I; Borghini-Fuhrer I; Fofana B; Camara D; Somé AF; Coulibaly AS; Traore OB; Dara N; Kabore MJT; Thera I; Compaore YD; Sylla MM; Nikiema F; Diallo MS; Dicko A; Gil JP; Borrmann S; Duparc S; Miller RM; Doumbo OK; Shin J; Bjorkman A; Ouedraogo J-B; Sirima SB; Djimdé AA
Article: AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE. 2015;92(6):1202-1206

Polymorphisms in the K13-propeller gene in artemisinin-susceptible Plasmodium falciparum parasites from Bougoula-Hameau and Bandiagara, Mali.

Ouattara A; Kone A; Adams M; Fofana B; Maiga AW; Hampton S; Coulibaly D; Thera MA; Diallo N; Dara A; Sagara I; Gil JP; Bjorkman A; Takala-Harrison S; Doumbo OK; Plowe CV; Djimde AA
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2015;59(1):96-104

Carboxymefloquine, the major metabolite of the antimalarial drug mefloquine, induces drug-metabolizing enzyme and transporter expression by activation of pregnane X receptor.

Piedade R; Traub S; Bitter A; Nüssler AK; Gil JP; Schwab M; Burk O
Article: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015;70(1):116-123

Alternatively spliced transcripts and novel pseudogenes of the Plasmodium falciparum resistance-associated locus pfcrt detected in East African malaria patients.

Gadalla NB; Malmberg M; Adam I; Oguike MC; Beshir K; Elzaki S-E; Mukhtar I; Gadalla AA; Warhurst DC; Ngasala B; Mårtensson A; El-Sayed BB; Gil JP; Sutherland CJ
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2014;58(12):7390-7397

Complex polymorphisms in the Plasmodium falciparum multidrug resistance protein 2 gene and its contribution to antimalarial response.

Veiga MI; Osório NS; Ferreira PE; Franzén O; Dahlstrom S; Lum JK; Nosten F; Gil JP
Article: INTERNATIONAL JOURNAL OF BIOSTATISTICS. 2013;9(1):135-148

On the effects of malaria treatment on parasite drug resistance--probability modelling of genotyped malaria infections.

Kum CK; Thorburn D; Ghilagaber G; Gil P; Björkman A
Article: MALARIA JOURNAL. 2013;12:106

Rapid diagnostic tests for molecular surveillance of Plasmodium falciparum malaria -assessment of DNA extraction methods and field applicability.

Morris U; Aydin-Schmidt B; Shakely D; Mårtensson A; Jörnhagen L; Ali AS; Msellem MI; Petzold M; Gil JP; Ferreira PE; Björkman A
Article: MALARIA JOURNAL. 2013;12:103

Temporal trends of molecular markers associated with artemether-lumefantrine tolerance/resistance in Bagamoyo district, Tanzania.

Malmberg M; Ngasala B; Ferreira PE; Larsson E; Jovel I; Hjalmarsson A; Petzold M; Premji Z; Gil JP; Björkman A; Mårtensson A
Article: JOURNAL OF INFECTIOUS DISEASES. 2013;207(5):842-847

Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its association with pfmdr1 polymorphisms.

Malmberg M; Ferreira PE; Tarning J; Ursing J; Ngasala B; Björkman A; Mårtensson A; Gil JP
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2013;57(2):887-892

Assessing the cost-benefit effect of a Plasmodium falciparum drug resistance mutation on parasite growth in vitro.

Fröberg G; Ferreira PE; Mårtensson A; Ali A; Björkman A; Gil JP
Article: JOURNAL OF INFECTIOUS DISEASES. 2013;207(3):520-527

Quinine treatment selects the pfnhe-1 ms4760-1 polymorphism in Malian patients with Falciparum malaria.

Kone A; Mu J; Maiga H; Beavogui AH; Yattara O; Sagara I; Tekete MM; Traore OB; Dara A; Dama S; Diallo N; Kodio A; Traoré A; Björkman A; Gil JP; Doumbo OK; Wellems TE; Djimde AA
Article: DRUG METABOLISM AND PHARMACOKINETICS. 2013;28(6):519-521

Frequency of the functionally relevant aryl hydrocarbon receptor repressor (AhRR) Pro185Ala SNP in Papua New Guinea.

Cavaco I; Hombhanje FW; Gil JP; Kaneko A
Article: BRITISH JOURNAL OF PHARMACOLOGY. 2012;167(3):666-681

Differential effects of clinically used derivatives and metabolites of artemisinin in the activation of constitutive androstane receptor isoforms.

Burk O; Piedade R; Ghebreghiorghis L; Fait JT; Nussler AK; Gil JP; Windshügel B; Schwab M
Article: MALARIA JOURNAL. 2012;11:321

Decreased prevalence of Plasmodium falciparum resistance markers to amodiaquine despite its wide scale use as ACT partner drug in Zanzibar.

Fröberg G; Jörnhagen L; Morris U; Shakely D; Msellem MI; Gil JP; Björkman A; Mårtensson A
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2012;56(7):3615-3619

pfmdr1 amplification is related to increased Plasmodium falciparum in vitro sensitivity to the bisquinoline piperaquine.

Veiga MI; Ferreira PE; Malmberg M; Jörnhagen L; Björkman A; Nosten F; Gil JP
Article: TROPICAL MEDICINE & INTERNATIONAL HEALTH. 2012;17(7):854-857

Cytochrome 1A1 and 1B1 gene diversity in the Zanzibar islands.

Cavaco I; Piedade R; Msellem MI; Bjorkman A; Gil JP
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2012;56(4):2153-2157

PXR variants and artemisinin use in Vietnamese subjects: frequency distribution and impact on the interindividual variability of CYP3A induction by artemisinin.

Piedade R; Schaeffeler E; Winter S; Asimus S; Schwab M; Ashton M; Burk O; Gil JP
Article: MALARIA JOURNAL. 2011;10:380

Plasmodium falciparum population dynamics during the early phase of anti-malarial drug treatment in Tanzanian children with acute uncomplicated malaria.

Carlsson AM; Ngasala BE; Dahlström S; Membi C; Veiga IM; Rombo L; Abdulla S; Premji Z; Gil JP; Björkman A; Mårtensson A
Article: MEMORIAS DO INSTITUTO OSWALDO CRUZ. 2011;106 Suppl 1:123-129

Sentinel network for monitoring in vitro susceptibility of Plasmodium falciparum to antimalarial drugs in Colombia: a proof of concept.

Aponte SL; Díaz G; Pava Z; Echeverry DF; Ibarguen D; Rios M; Murcia LM; Quelal C; Murillo C; Gil P; Björkman A; Osorio L
Article: CLINICAL INFECTIOUS DISEASES. 2011;52(7):873-882

Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children <5 years of age with acute uncomplicated Plasmodium falciparum malaria in rural Tanzania: a randomized trial.

Ngasala BE; Malmberg M; Carlsson AM; Ferreira PE; Petzold MG; Blessborn D; Bergqvist Y; Gil JP; Premji Z; Björkman A; Mårtensson A
Article: MALARIA JOURNAL. 2011;10:64

Effectiveness of artemether-lumefantrine provided by community health workers in under-five children with uncomplicated malaria in rural Tanzania: an open label prospective study.

Ngasala BE; Malmberg M; Carlsson AM; Ferreira PE; Petzold MG; Blessborn D; Bergqvist Y; Gil JP; Premji Z; Mårtensson A
Article: PLOS ONE. 2011;6(5):e20212

Novel polymorphisms in Plasmodium falciparum ABC transporter genes are associated with major ACT antimalarial drug resistance.

Veiga MI; Ferreira PE; Jörnhagen L; Malmberg M; Kone A; Schmidt BA; Petzold M; Björkman A; Nosten F; Gil JP
Article: PLOS ONE. 2011;6(9):e23875

PfMDR1: mechanisms of transport modulation by functional polymorphisms.

Ferreira PE; Holmgren G; Veiga MI; Uhlén P; Kaneko A; Gil JP
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2010;54(11):4780-4788

Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania.

Hietala SF; Mårtensson A; Ngasala B; Dahlström S; Lindegårdh N; Annerberg A; Premji Z; Färnert A; Gil P; Björkman A; Ashton M
Article: PLOS ONE. 2010;5(8):e12408

Antimalarial exposure delays Plasmodium falciparum intra-erythrocytic cycle and drives drug transporter genes expression.

Veiga MI; Ferreira PE; Schmidt BA; Ribacke U; Björkman A; Tichopad A; Gil JP
Article: JOURNAL OF INFECTIOUS DISEASES. 2009;200(9):1456-1464

Plasmodium falciparum multidrug resistance protein 1 and artemisinin-based combination therapy in Africa.

Dahlström S; Ferreira PE; Veiga MI; Sedighi N; Wiklund L; Mårtensson A; Färnert A; Sisowath C; Osório L; Darban H; Andersson B; Kaneko A; Conseil G; Björkman A; Gil JP
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2009;53(6):2553-2556

Polymorphism in PfMRP1 (Plasmodium falciparum multidrug resistance protein 1) amino acid 1466 associated with resistance to sulfadoxine-pyrimethamine treatment.

Dahlström S; Veiga MI; Mårtensson A; Björkman A; Gil JP
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2009;65(4):355-363

Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam.

Veiga MI; Asimus S; Ferreira PE; Martins JP; Cavaco I; Ribeiro V; Hai TN; Petzold MG; Björkman A; Ashton M; Gil JP
Article: PHARMACOGENOMICS. 2008;9(10):1385-1390

Amodiaquine pharmacogenetics.

Gil JP
Article: INFECTION GENETICS AND EVOLUTION. 2008;8(3):340-345

Diversity of the sarco/endoplasmic reticulum Ca(2+)-ATPase orthologue of Plasmodium falciparum (PfATP6).

Dahlström S; Veiga MI; Ferreira P; Mårtensson A; Kaneko A; Andersson B; Björkman A; Gil JP
Article: THERAPEUTIC DRUG MONITORING. 2008;30(1):10-15

Polymorphism of antimalaria drug metabolizing, nuclear receptor, and drug transport genes among malaria patients in Zanzibar, East Africa.

Ferreira PE; Veiga MI; Cavaco I; Martins JP; Andersson B; Mushin S; Ali AS; Bhattarai A; Ribeiro V; Björkman A; Gil JP
Article: TRENDS IN PARASITOLOGY. 2008;24(2):49-51

Carriers, channels and chloroquine efficacy in Guinea-Bissau.

Ursing J; Rombo L; Kofoed P-E; Gil JP
Article: ASIAN BIOMEDICINE. 2008;2(2):117-121

Mixed-species malaria infection in high transmission areas of Thailand

Congpuong K; Gil JP; Bualombai P; Kangchaingone Y; Darakapong A; Wernsdorfer WH
Article: AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE. 2007;77(6):1034-1038

Short report: polymorphisms in the pfcrt and pfmdr1 genes of Plasmodium falciparum and in vitro susceptibility to amodiaquine and desethylamodiaquine.

Echeverry DF; Holmgren G; Murillo C; Higuita JC; Björkman A; Gil JP; Osorio L
Article: INFECTION GENETICS AND EVOLUTION. 2007;7(5):562-569

Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in East Africa.

Holmgren G; Hamrin J; Svärd J; Mårtensson A; Gil JP; Björkman A
Article: INFECTION GENETICS AND EVOLUTION. 2007;7(5):555-561

Chloroquine resistant P. falciparum prevalence is low and unchanged between 1990 and 2005 in Guinea-Bissau: an effect of high chloroquine dosage?

Ursing J; Schmidt BA; Lebbad M; Kofoed P-E; Dias F; Gil JP; Rombo L
Article: TROPICAL MEDICINE & INTERNATIONAL HEALTH. 2007;12(6):736-742

The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa.

Sisowath C; Ferreira PE; Bustamante LY; Dahlström S; Mårtensson A; Björkman A; Krishna S; Gil JP
Article: AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE. 2007;76(5):844-848

Plasmodium falciparum genotypes associated with chloroquine and amodiaquine resistance in Guinea-Bissau.

Ursing J; Kofoed P-E; Rodrigues A; Rombo L; Gil JP
Article: PHARMACOGENOMICS. 2007;8(2):187-198

CYP2C8 and antimalaria drug efficacy.

Gil JP; Gil Berglund E
Article: TROPICAL MEDICINE & INTERNATIONAL HEALTH. 2006;11(12):1808-1812

Amodiaquine resistance is not related to rare findings of pfmdr1 gene amplifications in Kenya.

Holmgren G; Björkman A; Gil JP
Article: INFECTION GENETICS AND EVOLUTION. 2006;6(4):309-314

Amodiaquine resistant Plasmodium falciparum malaria in vivo is associated with selection of pfcrt 76T and pfmdr1 86Y.

Holmgren G; Gil JP; Ferreira PM; Veiga MI; Obonyo CO; Björkman A
Article: MOLECULAR AND CELLULAR PROBES. 2006;20(2):100-104

Multiplex PCR-RFLP methods for pfcrt, pfmdr1 and pfdhfr mutations in Plasmodium falciparum.

Veiga MI; Ferreira PE; Björkman A; Gil JP
Article: ACTA TROPICA. 2006;97(3):352-356

Quinoline resistance associated polymorphisms in the pfcrt, pfmdr1 and pfmrp genes of Plasmodium falciparum in Iran.

Ursing J; Zakeri S; Gil JP; Björkman A
Article: CLINICAL CHEMISTRY AND LABORATORY MEDICINE. 2006;44(2):168-170

CYP2C8 polymorphism among the Portuguese.

Cavaco I; Piedade R; Gil JP; Ribeiro V
Article: CLINICAL INFECTIOUS DISEASES. 2005;41(8):1079-1086

Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania.

Mårtensson A; Strömberg J; Sisowath C; Msellem MI; Gil JP; Montgomery SM; Olliaro P; Ali AS; Björkman A
Article: TROPICAL MEDICINE & INTERNATIONAL HEALTH. 2005;10(10):1060-1064

Multiple genotypes of the merozoite surface proteins 1 and 2 in Plasmodium falciparum infections in a hypoendemic area in Iran.

Zakeri S; Bereczky S; Naimi P; Pedro Gil J; Djadid ND; Färnert A; Snounou G; Björkman A
Article: JOURNAL OF INFECTIOUS DISEASES. 2005;191(6):1014-1017

In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem).

Sisowath C; Strömberg J; Mårtensson A; Msellem M; Obondo C; Björkman A; Gil JP
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2005;61(1):15-18

CYP2C8 polymorphism frequencies among malaria patients in Zanzibar.

Cavaco I; Strömberg-Nörklit J; Kaneko A; Msellem MI; Dahoma M; Ribeiro VL; Bjorkman A; Gil JP
Article: AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE. 2005;72(3):249-251

Short report: Rapid DNA extraction from archive blood spots on filter paper for genotyping of Plasmodium falciparum.

Bereczky S; Mårtensson A; Gil JP; Färnert A
Article: ACTA TROPICA. 2005;93(3):221-231

Pharmacodynamic interactions of amodiaquine and its major metabolite desethylamodiaquine with artemisinin, quinine and atovaquone in Plasmodium falciparum in vitro.

Mariga ST; Gil JP; Wernsdorfer WH; Björkman A
Article: TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE. 2005;99(1):62-70

In vitro recrudescence of Plasmodium falciparum parasites suppressed to dormant state by atovaquone alone and in combination with proguanil.

Thapar MM; Gil JP; Björkman A
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2004;48(11):4089-4096

Synergism between amodiaquine and its major metabolite, desethylamodiaquine, against Plasmodium falciparum in vitro.

Mariga ST; Gil JP; Sisowath C; Wernsdorfer WH; Björkman A
Article: ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY. 2004;98(3):293-296

High frequency of the genetic polymorphisms associated with sulfadoxine-pyrimethamine resistance, among Plasmodium falciparum isolates from São Tomé and Príncipe, West Africa.

Cravo P; Figueiredo S; Nogueira F; Lopes D; Ferreira ID; Ferreira C; Gil JP; do Rosario VE
Article: MOLECULAR AND CELLULAR PROBES. 2003;17(2-3):85-89

Detection of atovaquone and Malarone resistance conferring mutations in Plasmodium falciparum cytochrome b gene (cytb).

Gil JP; Nogueira F; Strömberg-Nörklit J; Lindberg J; Carrolo M; Casimiro C; Lopes D; Arez AP; Cravo PV; Rosário VE
Article: BMJ-BRITISH MEDICAL JOURNAL. 2003;326(7390):628-629

Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports.

Färnert A; Lindberg J; Gil P; Swedberg G; Berqvist Y; Thapar MM; Lindegårdh N; Berezcky S; Björkman A
Article: ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY. 2002;96(8):831-834

pfcrt and pfmdr1 mutations and chloroquine resistance in Plasmodium falciparum from São Tomé and Príncipe, West Africa.

Lopes D; Nogueira F; Gil JP; Ferreira C; do Rosário VE; Cravo P
Article: MALARIA JOURNAL. 2002;1:12

Molecular characterisation of drug-resistant Plasmodium falciparum from Thailand.

Lopes D; Rungsihirunrat K; Nogueira F; Seugorn A; Gil JP; do Rosário VE; Cravo P
Article: PHARMACOGENETICS AND GENOMICS. 1999;9(1):9-15

N-acetyltransferase (NAT2) genotype and susceptibility of sporadic Alzheimer's disease.

Rocha L; Garcia C; de Mendonça A; Gil JP; Bishop DT; Lechner MC
Article: CARCINOGENESIS. 1998;19(1):37-41

Increased frequency of wild-type arylamine-N-acetyltransferase allele NAT2*4 homozygotes in Portuguese patients with colorectal cancer.

Gil JP; Lechner MC
Visa fler

Alla övriga publikationer

Letter: JOURNAL OF TRAVEL MEDICINE. 2022;29(4):taac058

Ketoconazole increases atovaquone exposure following concomitant administration with Malarone® in healthy subjects.

Thapar MM; Ursing J; Ashton M; Bergqvist Y; Gil JP; Björkman A
Review: EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY. 2022;18(1):39-59

An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malaria.

Pernaute-Lau L; Camara M; Nóbrega de Sousa T; Morris U; Ferreira MU; Gil JP
Review: ACS SENSORS. 2021;6(11):3898-3911

The Future in Sensing Technologies for Malaria Surveillance: A Review of Hemozoin-Based Diagnosis.

Baptista V; Costa MS; Calçada C; Silva M; Gil JP; Veiga MI; Catarino SO
Review: FRONTIERS IN PHARMACOLOGY. 2021;12:759422

Plasmodium falciparum Multidrug Resistance Proteins (pfMRPs).

Gil JP; Fançony C
Letter: EMERGING INFECTIOUS DISEASES. 2018;24(8):1591-1593

Plasmodium falciparum Plasmepsin 2 Duplications, West Africa.

Inoue J; Silva M; Fofana B; Sanogo K; Mårtensson A; Sagara I; Björkman A; Veiga MI; Ferreira PE; Djimde A; Gil JP
Review: EXPERT REVIEW OF ANTI-INFECTIVE THERAPY. 2017;15(6):527-543

pfmdr1 (Plasmodium falciparum multidrug drug resistance gene 1): a pivotal factor in malaria resistance to artemisinin combination therapies.

Gil JP; Krishna S
Review: MALARIA JOURNAL. 2016;15:74

Plasmodium falciparum drug resistance in Angola.

Fançony C; Brito M; Gil JP
Review: BMC MEDICINE. 2015;13:212

Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data.

WWARN Artemisinin based Combination Therapy (ACT) ; Dahal P; d'Alessandro U; Dorsey G; Guerin PJ; Nsanzabana C; Price RN; Sibley CH; Stepniewska K; Talisuna AO
Review: LANCET INFECTIOUS DISEASES. 2015;15(6):692-702

The effect of dose on the antimalarial efficacy of artemether-lumefantrine: a systematic review and pooled analysis of individual patient data.

Worldwide Antimalarial Resistance Network (WWARN)
Review: TRENDS IN PARASITOLOGY. 2013;29(7):318-320

Artemisinin resistance in Plasmodium falciparum: what is it really?

Ferreira PE; Culleton R; Gil JP; Meshnick SR
Editorial comment: PHARMACOGENOMICS. 2013;14(7):707-710

Malaria pharmacogenomics: return to the future.

Gil JP
Letter: JOURNAL OF INFECTIOUS DISEASES. 2013;207(4):687-688

CYP2C8 status of patients with malaria influences selection of Plasmodium falciparum pfmdr1 alleles after amodiaquine-artesunate treatment.

Cavaco I; Mårtensson A; Fröberg G; Msellem M; Björkman A; Gil JP
Review: EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY. 2011;7(10):1185-1200

The pharmacogenetics of antimalaria artemisinin combination therapy.

Piedade R; Gil JP
Review: LANCET INFECTIOUS DISEASES. 2009;9(12):760-774

Pharmacogenetics of antimalarial drugs: effect on metabolism and transport.

Kerb R; Fux R; Mörike K; Kremsner PG; Gil JP; Gleiter CH; Schwab M
Published paper: JOURNAL OF INFECTIOUS DISEASES. 2009;199(5):750-757

In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa.

Sisowath C; Petersen I; Veiga MI; Mårtensson A; Premji Z; Björkman A; Fidock DA; Gil JP
Review: PERSONALIZED MEDICINE. 2008;5(6):627-639

Pharmacogenetic tools for malaria and TB in the Developing World.

Ferreira PE; Cavaco I; Gil JP
Letter: CLINICAL CHEMISTRY. 2007;53(11):1977-1979

The Vietnamese Khin population harbors particular N-acetyltransferase 2 allele frequencies.

Cavaco I; Asimus S; Peyrard-Janvid M; Ferreira PE; Veiga MI; Hai TN; Ribeiro V; Ashton M; Gil JP
Letter: JOURNAL OF INFECTIOUS DISEASES. 2006;194(5):716-718

No pfmdr1 amplifications in samples from Guinea-Bissau and Liberia collected between 1981 and 2004.

Ursing J; Kofoed P-E; Rombo L; Gil JP
Letter: JOURNAL OF INFECTIOUS DISEASES. 2005;192(7):1304-1305

Coartem (Artemether-Lumefantrine) in Africa:: The beginning of the end?: Response

Gil JP; Sisowath C; Björkman A
Letter: JOURNAL OF INFECTIOUS DISEASES. 2003;187(11):1828-1829

High prevalence of double Plasmodium falciparum dhfr mutations at codons 108 and 59 in the Sistan-Baluchistan province, Iran.

Zakeri S; Gil JP; Bereckzy S; Djadid ND; Bjorkman A
Published paper: CLINICAL CHEMISTRY AND LABORATORY MEDICINE. 2003;41(4):606-609

CYP3A4*1B and NAT2*14 alleles in a native African population.

Cavaco I; Reis R; Gil JP; Ribeiro V
Published paper: CLINICAL CHEMISTRY AND LABORATORY MEDICINE. 2003;41(10):1345-1350

CYP3A4 and MDR1 alleles in a Portuguese population.

Cavaco I; Gil JP; Gil-Berglund E; Ribeiro V
Review: TROPICAL MEDICINE & INTERNATIONAL HEALTH. 2002;7(5):395-408

Genetic diversity of Plasmodium falciparum: asexual stages.

Meyer CG; May J; Arez AP; Gil JP; Do Rosario V
Visa fler

Anställningar

Senior Forskare, Institutionen för mikrobiologi, tumör- och cellbiologi, Karolinska Institutet, 2022-

Examina och utbildning

Docent, Farmakologi, Karolinska Institutet, 2014

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI